| pubmed-article:8017894 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8017894 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8017894 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8017894 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:8017894 | lifeskim:mentions | umls-concept:C0751967 | lld:lifeskim |
| pubmed-article:8017894 | lifeskim:mentions | umls-concept:C0031082 | lld:lifeskim |
| pubmed-article:8017894 | lifeskim:mentions | umls-concept:C1707501 | lld:lifeskim |
| pubmed-article:8017894 | pubmed:dateCreated | 1994-7-28 | lld:pubmed |
| pubmed-article:8017894 | pubmed:abstractText | Serial monthly contrast-enhanced MRIs were performed in 10 early relapsing-remitting patients with multiple sclerosis and 2 patients with chronic progressive disease for a period of 12 to 55 months. MRI was performed at 1.5 T using contiguous 5-mm slices with pre- and postgadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) T1-weighted and T2-weighted images. New and total number of Gd-DTPA-enhancing lesions were numbered and counted and lesion areas were correlated to an increase of > or = 0.5 in Expanded Disability Status Scale (EDSS) scores. The frequency of enhancing lesions varied from patient to patient; however, there was a correlation between a burst of enhancing lesion number and area above the individual's mean lesion frequency to an increase in EDSS score. A bootstrap analysis of the lesion count was performed to develop a statistical basis for determining population sizes for treatment trials. These results provide a basis for the potential use of contrast-enhanced MRI as a primary outcome measure in phase II treatment trials involving patients with relapsing-remitting MS. | lld:pubmed |
| pubmed-article:8017894 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8017894 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8017894 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8017894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8017894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8017894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8017894 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8017894 | pubmed:issn | 0364-5134 | lld:pubmed |
| pubmed-article:8017894 | pubmed:author | pubmed-author:SmithM EME | lld:pubmed |
| pubmed-article:8017894 | pubmed:author | pubmed-author:McFarlandH... | lld:pubmed |
| pubmed-article:8017894 | pubmed:author | pubmed-author:AlbertP SPS | lld:pubmed |
| pubmed-article:8017894 | pubmed:author | pubmed-author:MaloneTT | lld:pubmed |
| pubmed-article:8017894 | pubmed:author | pubmed-author:StoneL ALA | lld:pubmed |
| pubmed-article:8017894 | pubmed:author | pubmed-author:FrankJ AJA | lld:pubmed |
| pubmed-article:8017894 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8017894 | pubmed:volume | 36 Suppl | lld:pubmed |
| pubmed-article:8017894 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8017894 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8017894 | pubmed:pagination | S86-90 | lld:pubmed |
| pubmed-article:8017894 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:meshHeading | pubmed-meshheading:8017894-... | lld:pubmed |
| pubmed-article:8017894 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8017894 | pubmed:articleTitle | Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. | lld:pubmed |
| pubmed-article:8017894 | pubmed:affiliation | Laboratory of Diagnostic Radiology Research, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD 20892. | lld:pubmed |
| pubmed-article:8017894 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8017894 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8017894 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8017894 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8017894 | lld:pubmed |
